FREE Account Opening + No Clearing Fees
Loading...

Trident Texofab IPO vs Vanta Bioscience IPO

Comparision between Trident Texofab IPO and Vanta Bioscience IPO.

IPO Details

Trident Texofab IPO is a SME Fixed Price Issue IPO proposed to list at BSE SME while Vanta Bioscience IPO is a SME Fixed Price Issue proposed to list at BSE SME.

  Trident Texofab IPO Vanta Bioscience IPO
Logo Trident Texofab IPO Logo Vanta Bioscience IPO Logo
Issue Category SME SME
Issue Type IPO IPO
Process Type Fixed Price Issue Fixed Price Issue
Listing At BSE SME BSE SME
Lead Managers Oneview Corporate Advisors Pvt. Ltd. Inventure Merchant Banker Services Pvt Ltd
Registrar Kfin Technologies Limited Bigshare Services Pvt Ltd
Market Maker
DRHP DRHP DRHP
RHP RHP RHP
Anchor Investor
IPO Allotment URL

Issue Size and Price

The total issue size of Trident Texofab IPO is up to ₹3.53 Cr whereas the issue size of the Vanta Bioscience IPO is up to ₹7.56 Cr. The final issue price of Trident Texofab IPO is ₹30.00 per share and of Vanta Bioscience IPO is ₹50.00 per share.

  Trident Texofab IPO Vanta Bioscience IPO
Face Value ₹10 per share ₹10 per share
Issue Price (Lower)
Issue Price (Upper)
Issue Price (Final) ₹30.00 per share ₹50.00 per share
Discount (Retail)
Discount (Employee)
Market Lot Size 4000 shares 3000 shares
Fresh Issue Size
Fresh Issue Size (Amount)
OFS Issue Size
OFS Issue Size (Amount)
Issue Size Total 11,76,000 shares 15,12,000 shares
Issue Size Total (Amount) up to ₹3.53 Cr up to ₹7.56 Cr

IPO Timetable

Trident Texofab IPO opens on Sep 21, 2017, while Vanta Bioscience IPO opens on Sep 25, 2017. The closing date of Trident Texofab IPO and Vanta Bioscience IPO is Sep 26, 2017, and Sep 27, 2017, respectively.

  Trident Texofab IPO Vanta Bioscience IPO
Anchor Bid Date
Issue Open Sep 21, 2017 Sep 25, 2017
Issue Close Sep 26, 2017 Sep 27, 2017
Basis Of Allotment (Tentative)
Initiation of Refunds (Tentative)
Credit of Share (Tentative)
Listing date (Tentative)
Anchor Lockin End date 1
Anchor Lockin End date 2

Financials

Trident Texofab IPO P/E ratio is , as compared to Vanta Bioscience IPO P/E ratio of .

  Trident Texofab IPO Vanta Bioscience IPO
Financial
Promoter Shareholding (Pre-Issue)
Promoter Shareholding (Post-Issue)
P/E Ratio
Market Cap
ROE
ROCE
Debt/Equity
EPS
RoNW

Shares Offered

In the Trident Texofab IPO retail investors (RII) are offered while in Vanta Bioscience IPO retail investors are offered . Qualified institutional buyers (QIB) are offered in Trident Texofab IPO and in Vanta Bioscience IPO.

  Trident Texofab IPO Vanta Bioscience IPO
Anchor Investor Reserveration
Market Maker Reserveration
QIB
NII
RII
Employee
Others
Total

Bids Received (Subscription)

Trident Texofab IPO subscribed in total, whereas Vanta Bioscience IPO subscribed .

  Trident Texofab IPO Vanta Bioscience IPO
QIB (times)
NII (times)
Big NII (times)
Small NII (times)
RII (times)
Employee (times)
Other (times)
Total (times)

Comments

Add a public comment...